PriceSensitive

TALi Digital (ASX:TD1) collaborates with Duke Clinical Research Institute for learning platforms

Health Care
ASX:TD1      MCAP $6.59M
22 June 2020 14:15 (AEST)
TALi Digital (ASX:TD1) - Managing Director, Glenn Smith

Source: TechInvest

TALi Digital (TD1) will work with the Duke Clinical Research Institute (DCRI) to conduct clinical research programs to evaluate TALi’s technology platform.

The Duke Clinical Research Institute is part of the Duke University School of Medicine and is the world’s largest academic clinical research organisation.

“We are excited to work with the DCRI, which has a proven track record of designing innovative large-scale, longitudinal studies for cognitive disorders in paediatric populations,” TALi Managing Director Glenn Smith said.

TALi Digital, formerly called Novita Healthcare, is a leading health technology company with a focus on improving learning and cognitive skills for early childhood-aged children.

Its two main platforms, TALi Train and TALi Detect, are game-based platforms which test and improve a child’s attention span, maintain focus, prevent impulsive behaviour, avoid distractions and fidgeting, and improve learning at school.

This collaboration will collect international clinical evidence of the benefits of these platforms.

“We welcome the opportunity to develop clinical research studies that will expand the clinical evidence base for novel and innovative digital tools to identify and treat the symptoms of inattention at a young age,” Duke Professor in Psychiatry and Behavioral Sciences and DCRI Digital Health Solutions Co-Director Professor Scott Kollins said.

“Collaborations like the one with the DCRI demonstrate the potential for TALi to have a tremendous impact on the lives of children and their broader communities,” Scott added.

The first collaboration project will begin this year.

Company shares are up 3.85 per cent and are trading for 2.7 cents each at 1:35 pm AEST.

Related News